Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$471.85 USD

471.85
1,418,197

+1.77 (0.38%)

Updated Aug 11, 2025 04:00 PM ET

After-Market: $471.75 -0.10 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (148 out of 244)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AMN Healthcare (AMN) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

AMN Healthcare (AMN) issues upbeat revenue guidance for the third quarter of 2019.

Zacks Equity Research

Syneos Health (SYNH) Q2 Earnings Beat Estimates, '19 View Up

by Zacks Equity Research

We are upbeat about Syneos Health's (SYNH) strong year-over-year revenue growth across both operating segments.

Zacks Equity Research

Insulet (PODD) Misses on Q2 Earnings, Ups '19 Revenue View

by Zacks Equity Research

The year-over-year improvement in Insulet's (PODD) revenues owing to the solid adoption of Omnipod system, both in the United States and the international markets, encourages us.

Zacks Equity Research

STERIS (STE) Q1 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

STERIS (STE) witnesses solid revenue growth across each of its operating segments in Q1.

Zacks Equity Research

Henry Schein (HSIC) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Henry Schein (HSIC) sees solid performance by the global Medical and Technology and Value-added Services businesses in Q2.

Zacks Equity Research

Becton, Dickinson (BDX) Beats on Q3 Earnings and Revenues

by Zacks Equity Research

Strong contributions from BD Medical and Interventional units drive Becton, Dickinson???s (BDX) fiscal third quarter.

Zacks Equity Research

The Zacks Analyst Blog Highlights: DIS, CBS, KHC, TSN, DVN, PXD, ISRG, SUHJY and HTHIY

by Zacks Equity Research

The Zacks Analyst Blog Highlights: DIS, CBS, KHC, TSN, DVN, PXD, ISRG, SUHJY and HTHIY

John Blank headshot

Global Week Ahead: An Update On Q2 Earnings

by John Blank

Q2 earnings growth is tracking modestly above what we saw in Q1. Revenue growth is almost even between Q1 and Q2.

Zacks Equity Research

Hill-Rom (HRC) Beats on Q3 Earnings, Tightens '19 Guidance

by Zacks Equity Research

Hill-Rom (HRC) registers a solid year-over-year increase in revenues on robust domestic growth.

Zacks Equity Research

Integer Holdings (ITGR) Q2 Earnings Beat, Revenues Miss

by Zacks Equity Research

Higher revenues and strong 2019 outlook benefit Integer Holdings' (ITGR) Q2 earnings.

Zacks Equity Research

HMS Holdings (HMSY) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Higher revenues, gross margin expansion and raised 2019 outlook benefit HMS Holdings' (HMSY) Q2 earnings.

Zacks Equity Research

Intersect (XENT) Q2 Loss Wider Than Estimates, Revenues Miss

by Zacks Equity Research

Intersect ENT's (XENT) lowered revenue guidance for 2019 raises concern.

Zacks Equity Research

PRA Health (PRAH) Q2 Earnings Beat, EPS Guidance Narrowed

by Zacks Equity Research

PRA Health (PRAH) slashes 2019 revenue guidance; direct costs surge in second quarter.

Zacks Equity Research

Teleflex (TFX) Q2 Earnings Top Estimates, Margins Improve

by Zacks Equity Research

Teleflex (TFX) sees robust revenue improvement across majority of segments and all geographies.

Zacks Equity Research

Teleflex (TFX) Q2 Earnings Top Estimates, Margins Improve

by Zacks Equity Research

Teleflex (TFX) sees robust revenue improvement across majority of segments and all geographies.

Zacks Equity Research

Globus Medical (GMED) Q2 Earnings In Line, Revenue View Up

by Zacks Equity Research

Globus Medical's (GMED) spine business gains traction from solid worldwide growth in the second quarter.

Zacks Equity Research

Genomic Health (GHDX) to Join Exact Sciences, Posts Q2 Results

by Zacks Equity Research

The merger of Genomic Health (GHDX) with Exact Sciences will combine two of the strongest brands in cancer diagnostics, Cologuard and OncotypeDX, providing platform for growth.

Zacks Equity Research

DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook benefit DexCom's (DXCM) Q2 earnings. However, contraction in gross margin remains a woe.

Zacks Equity Research

Bio-Rad (Bio) Q2 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

We are upbeat about Bio-Rad's (BIO) year-over-year revenue growth within the Clinical Diagnostics segment in Q2.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q2 Earnings Beat, Revenues Fall Y/Y

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) raises guidance for 2019 adjusted EPS.

Zacks Equity Research

Bruker (BRKR) Q2 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

Bruker (BRKR) registers strong year-over-year revenue growth across all segments and geographies.

Zacks Equity Research

Amedisys (AMED) Q2 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Robust year-over-year growth in Medicare and non-Medicare revenues aids Amedisys' (AMED) Home Health and Hospice divisions.

Zacks Equity Research

Hologic (HOLX) Beats on Q3 Earnings, Ups '19 Revenue View

by Zacks Equity Research

Hologic's (HOLX) strong top-line growth in Q3 is led by a solid year-over-year rise in core businesses like Breast Health and Molecular Diagnostics.

Zacks Equity Research

McKesson (MCK) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

McKesson's (MCK) Q1 results benefit from higher revenues and solid show by U.S. Pharmaceutical and Specialty, and Medical-Surgical Solutions.

Zacks Equity Research

AmerisourceBergen (ABC) Q3 Earnings & Revenues Top Estimates

by Zacks Equity Research

Higher revenues, segmental growth and raised 2019 EPS outlook benefit AmerisourceBergen's (ABC) Q3 earnings.